SEATTLE, Feb. 18, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR). “Recent research in our labs in both preclinical… Continue reading

Posted on February 18th, 2020 in Press Releases | Comments Off on LumiThera to Expand Research into Diabetic Retinopathy for Valeda® Light Delivery System

SEATTLE, Jan. 23, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Daniel Bertholet to the Board of Directors. “We are very excited to have Daniel Bertholet join our Board of Directors,” stated Clark Tedford, Ph.D., President and CEO.… Continue reading

Posted on January 26th, 2020 in Press Releases | Comments Off on LumiThera Adds Daniel Bertholet to Board of Directors

SEATTLE, Jan. 13, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2nd tranche of its Series C round of financing. The proceeds of the financing are being used to support further clinical testing and commercialization of its… Continue reading

Posted on January 15th, 2020 in Press Releases | Comments Off on LumiThera Closes 2nd Tranche of Series C Financing

SEATTLE, Oct. 1, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center study called LIGHTSITE III enrolled and treated the… Continue reading

Posted on October 2nd, 2019 in Press Releases | Comments Off on LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3–4 weeks) over 1 year. Outcome measures included best-corrected visual… Continue reading

Posted on August 22nd, 2019 in Research Articles | Comments Off on A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION

SEATTLE, June 12, 2019 /PRNewswire/ — LumiThera, Inc. and Product Creation Studio today announced that LumiThera’s Valeda Light Delivery System has been honored with a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2019 in conjunction with the MD&M… Continue reading

Posted on June 12th, 2019 in Press Releases | Comments Off on Valeda Light Delivery System Receives 2019 Medical Design Excellence Award

SEATTLE, April 11, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a European Union multi-center clinical study in dry Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center, post-marketing study called LIGHTSITE II enrolled and treated… Continue reading

Posted on April 12th, 2019 in Press Releases | Comments Off on LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration

SEATTLE, March 12, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of Seattle Business magazine’s 2019 Leaders in Health Care Award for Achievement in Medical Technology. Seattle Business magazine’s annual Leaders in Health Care Awards honor… Continue reading

Posted on March 12th, 2019 in Press Releases | Comments Off on LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology

SEATTLE, March 7, 2019 /PRNewswire/ — LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced an agreement with Andrec Corporation S.A. to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Colombia and several Latin America countries.… Continue reading

Posted on March 7th, 2019 in Press Releases | Comments Off on LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries

SEATTLE, Feb. 26, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute… Continue reading

Posted on February 26th, 2019 in Press Releases | Comments Off on LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration